Login / Register Order My Items
mob-logo
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Vaccine Peptide Synthesis

Custom epitope, long-peptide, peptide pool, and neoantigen synthesis for immunology research — from mg-scale screening to multi-gram and large-scale projects (up to 100 g+), with defined specifications and documented analytical verification.

Request a Quote Common targets Contact
Talk to a chemist Request a quote
Overview Peptide formats Use-cases Specs & scale Peptide pool QC Sequence inputs Capabilities QC Related services Contact

Overview

Vaccine peptides are synthetic peptide antigens used in immunology research for epitope mapping, immune stimulation assays, peptide pool screening, and neoantigen evaluation. [1], [2]

In preclinical immunology, peptides are used for epitope mapping, T-cell stimulation (e.g., ELISpot/ICS), antibody binding studies, and formulation feasibility. Many programs also use long peptides and peptide pools to broaden immunogenic coverage and support screening.

Epitope selection and validation commonly reference curated immune databases such as the Immune Epitope Database (IEDB) and related NIAID resources, which catalog experimentally validated T-cell and B-cell epitopes. [3]

Overlapping peptide libraries (e.g., 15-mers with defined overlap) are widely used to map antigenic regions and broaden coverage in ELISpot and intracellular cytokine staining (ICS) workflows. [4]

Epitope peptides Long peptides Peptide pools Neoantigen peptides HPLC / LC-MS QC
Peptide–antibody conjugation schematic showing peptide–linker attachment to an IgG antibody

Note: We synthesize vaccine peptides for research use by customer-provided sequence(s) and project-defined specifications.

Applications

T-cell epitope mapping

Define MHC class I/II epitopes, stimulate antigen-specific T cells, and compare variants.

Learn more about T-cell peptide libraries →

Peptide pool screening

Overlapping peptide sets or curated epitope pools for broad antigen coverage.

Explore peptide pool screening →

Neoantigen research

Custom mutation-derived peptides and long-peptide formats for cancer vaccine studies.

See neoantigen peptide →

Antibody/serology assays

Linear epitope peptides for binding assays, controls, and method development.

Formulation feasibility

Evaluate stability, solubility, and delivery constraints using defined peptide constructs.

Variant & conservation studies

Assess cross-reactivity and immune recognition across strains or sequence variants.

Peptide formats we commonly provide

Epitope peptides

Typically short peptides used in antigen-specific T-cell stimulation assays.

single epitope variant set

Long peptides

Longer sequences used in processing/presentation studies and multi-epitope designs.

long peptide multi-epitope

Peptide pools

Overlapping tiles or curated epitope pools for screening and immunogenicity profiling.

overlapping curated pools

If you already have IEDB IDs, UniProt positions, or immunoinformatics outputs, include them with your quote request for faster review. [1]

Use-cases we support

Epitope peptide synthesis (CD8/CD4)

Project-defined MHC class I and class II epitope peptides for stimulation assays (e.g., ELISpot/ICS), mapping, and benchmarking.

Overlapping peptide pools for ELISpot/ICS

Overlapping peptide sets and curated pools to broaden coverage and support efficient screening, including pool/subpool formats.

Neoantigen peptides for cancer vaccine research

Custom mutation-derived peptides, long-peptide formats, and matched controls for personalized vaccine and immunogenicity studies.

Variant / strain coverage panels

Variant-aware epitope panels and comparative sets to study cross-reactivity, conservation, and strain-to-strain differences.

Antibody epitope & serology peptides

Linear epitope peptides for binding assays, method development, and control reagents.

Custom panels & controls

Truncations, alanine scans, positional variants, and project-defined control sets to support SAR and reproducibility.

Sequence selection inputs we accept

Accepted formats

FASTA, CSV, or Excel. For pools/libraries, include peptide length, overlap, and target region coordinates (if applicable).

Helpful references

If you’re pulling sequences from IEDB, include IEDB IDs or exported lists and any supporting context. [1] For background on the IEDB resource, see NIAID’s overview. [4]

Common vaccine peptide targets (representative examples)

Below are representative research targets frequently used in immunology studies. We synthesize peptides based on your specified sequence(s), length, and intended use.

Area Antigen / Example Typical use Notes
Influenza A Matrix protein M1 (58–66): GILGFVFTL [2] CD8+ T-cell stimulation; assay controls Widely studied immunodominant epitope (HLA-A*02 context) [2]
COVID-19 research SARS-CoV-2 Spike / Nucleocapsid epitope sets Epitope screening; peptide pools Sequences are project-defined (variant-aware designs often used)
HPV research E6 / E7 peptide regions Oncoprotein epitope studies Often supplied as epitope panels or overlapping pools
Tuberculosis ESAT-6 / CFP-10 epitope vaccine research [5] Immunogenicity evaluation; antigen mapping Common TB antigens in vaccine research [5]
Cancer antigen NY-ESO-1 (157–165): SLLMWITQC [3] T-cell response studies; method development Well-studied HLA-A2 epitope reported in literature [3]
Neoantigens Mutation-derived peptides (custom) Personalized vaccine research Typically built from patient-specific variants and design constraints

Need help selecting sequences?

If you share the pathogen/protein target, HLA context (if known), and assay type, we can help you structure a practical set (single epitopes, variants, or pools) based on your objectives. IEDB is commonly used as a discovery and validation resource. [1,4]

Capabilities

Below is a practical summary of what we routinely support for vaccine peptide programs. If your program has non-standard requirements, include them in the quote request so we can confirm feasibility and recommended QC.

Specification Options / Notes Typical use
Peptide length Short epitope peptides and long peptides (project-defined length and format). CD8/CD4 epitopes, long-peptide designs, multi-epitope constructs
Purity tiers Crude, ≥95%, ≥98% (or project-defined purity target). Screening vs confirmatory assays; method development vs advanced programs
Scale From mg-scale research quantities to multi-gram and large-scale projects (up to 100 g+, sequence-dependent). Screening panels, pool production, program expansion and resupply
Formats Single peptides, panels, peptide pools/subpools, and long-peptide formats. Epitope mapping, ELISpot/ICS screening, neoantigen programs
Optional QC Project-defined add-ons such as solubility notes, residual TFA/counterion requests, and specialty testing when applicable. Workflow-specific documentation and release criteria alignment

Sequence inputs

FASTA/CSV/Excel lists are accepted. If available, include IEDB IDs/exports or UniProt positions to speed review. [1]

Design support

Share target, assay type (ELISpot/ICS/binding), and any HLA context. We can help structure epitopes vs pools vs long-peptides. IEDB and NIAID resources are commonly used for epitope selection workflows. [1,4]

Compatibility

Terminal caps, linkers/handles, conjugation-ready designs, and stability-oriented substitutions can be combined as requested (sequence-dependent).

Quality control & deliverables

Standard QC

Analytical HPLC/UPLC purity profile and LC-MS intact mass confirmation (when feasible).

Documentation

Project-defined documentation package (e.g., CoA, synthesis notes, handling guidance).

Panels & controls

Matched controls, variants, and pool compositions to support reproducibility.

Peptide pool composition & verification

Pre-pooling verification

Project-defined confirmation steps can be applied at the individual peptide level prior to pooling (e.g., LC-MS/HPLC checks where feasible).

Cross-contamination controls

Defined lists, traceable handling, and pool/subpool design choices help reduce ambiguity and support reproducibility.

Optional marker peptide confirmation

If your workflow benefits, we can discuss using marker peptides or a verification plan tailored to your pool design and assay sensitivity.

Pool QC approaches depend on pool size, peptide properties, and intended assay. Include your intended pool format and acceptance criteria in your quote request.

FAQ

What is a vaccine peptide?

A synthetic peptide antigen (often an epitope) used in immunology research to study or elicit specific immune responses. Epitope selection and validation commonly reference IEDB. [1]

What’s the difference between epitope peptides and long peptides?

Epitope peptides are typically short sequences used directly in stimulation assays, while long peptides are designed for processing/presentation workflows and may contain multiple epitopes.

What purity do I need for ELISpot/ICS?

Many screening workflows use crude or ≥95% depending on assay sensitivity and peptide properties. Confirmatory work commonly specifies ≥95% or ≥98%. Define your acceptance criteria in the quote request.

What is an overlapping peptide pool?

A pool built from overlapping peptides that tile across a protein/region to broaden coverage and support epitope mapping and screening.

How do I design 15-mers with 10-aa overlap?

A common approach is to generate 15-aa peptides that start every 5 residues across the target region (15 length minus 10 overlap = 5 step). Share the target sequence/region and we can help format the list.

Do you make epitope peptides, peptide pools, and neoantigen peptides?

Yes. We synthesize single epitopes, overlapping peptide sets, curated pools/subpools, and custom neoantigen peptides (including long-peptide formats) as requested.

What QC is provided?

Typical deliverables include analytical HPLC/UPLC purity profile and LC-MS intact mass confirmation (when feasible), plus documentation (e.g., CoA).

What sequence formats do you accept?

FASTA/CSV/Excel lists are accepted. If available, include IEDB exports/IDs, UniProt positions, and any HLA context to speed review. [1,4]

More FAQ'sAll FAQ's

Contact & quote request

Send project details

If you’re unsure which sequences to order, share the target (pathogen/protein/tumor antigen), desired coverage (epitopes vs pools), and any constraints (HLA context, variants, peptide length). We’ll help structure a practical build plan.

Email: sales@biosyn.com
Phone: +1 (800) 227-0627 | + (972) 420-8505

Fast quote checklist

  • Sequence(s) (FASTA/CSV OK) + terminal state (free/capped)
  • Format: single epitope / long peptide / pool / neoantigen set
  • Quantity and purity target
  • Use case: ELISpot/ICS, binding assay, screening, formulation
  • Any extras: linkers, conjugation handles, labels, special residues
Request a Quote Contact Us QC details

Recommended Reading & Literature References

References are provided for scientific background on epitope discovery, immune mapping, and peptide-based vaccine research (for context only; not clinical claims).

  • Vita, R. et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 2019, 47(D1), D339–D343. DOI
  • Sette, A.; Peters, B. Immune epitope mapping in the post-genomic era. Immunity 2007. DOI
  • National Institute of Allergy and Infectious Diseases (NIAID). Immune Epitope Database and Analysis Resource (IEDB). IEDB Resource
  • Kern, F. et al. Comprehensive identification of T cell epitopes using overlapping peptide libraries. J. Immunol. Methods.

E-E-A-T note: References are included for background on immune epitope mapping and peptide-based research workflows and do not imply clinical or therapeutic claims. Our services support custom peptide synthesis for research use.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links